J&J to Buy Firefly Bio for $1 Billion to Boost Oncology
Johnson and Johnson announced a 1 billion dollar cash deal to acquire biotech firm Firefly Bio and its specialized drug delivery platform. The technology targets KRAS-driven tumors with protein-degrading drugs to improve outcomes for hard-to-treat solid cancers.
Xurve View
Insights:
Xurve View
JOHNSON & JOHNSON will acquire biotech Firefly Bio for $1 billion in cash to expand its oncology pipeline. The deal centers on Firefly's Firelink platform, which targets KRAS-mutated solid tumors previously considered undruggable. This acquisition bolsters J&J’s capacity to treat high-unmet-need cancers, potentially extending survival rates currently measured in months.
